Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-Concept Study in Healthy Volunteers.

Trial Profile

Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-Concept Study in Healthy Volunteers.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Cannabidiol (Primary) ; Insulin (Primary) ; URB 597 (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Acronyms EICAS
  • Most Recent Events

    • 14 Aug 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017, as reported by ClinicalTrials.gov record.
    • 30 Jul 2013 Recruitment will recommence in Mar 2014, according to ClinicalTrials.gov record.
    • 30 Jul 2013 In a protocol amendment, sitagliptin was changed to URB 597, and the end date was changed to Dec 2016, according to the ClinicalTrials.gov.record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top